Liver Surgery: Early Complications—Liver Failure, Bile Leak and Sepsis
Liver resection remains to be the curative treatment of choice for both malignant and benign liver tumors. With advances in hepatic surgery and operative technique, liver resection has evolved from a rough and hasty procedure to a fine and delicate operation. Such surgical advances have resulted in a dramatic reduction of operative mortality, from over 50% in early series, to less than 10% in recent decades. Targeting a ‘zero’ mortality has even become a realistic goal to achieve. However, the postoperative complications rate remains largely unchanged over the years despite reduction in operative mortality and is in the range of 20–30%. Liver failure, bile leak and sepsis are serious complications that could lead to a fatal outcome. In this chapter, we will present our approach for prevention, diagnosis and management of these complications.
With adequate remnant liver volume and absence of co-morbid illness, liver failure is the most common cause of mortality after...
KeywordsIndocyanine green (ICG) clearance Liver function reserve Hepatectomy Portal vein embolization Liver failure Biliary complications
- 10.Hemming AW, Reed AI, Howard RJ, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237(5):681–91; discussion 691–683Google Scholar
- 18.Banners R, Nevens F, Larsen FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Herpetology. 2013;57(3):1153–62.Google Scholar
- 23.Calandra T, Baumgartner JD, Grau GE, et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferongamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis. 1990;161(5):982–7.CrossRefPubMedCentralGoogle Scholar
- 24.Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med. 1991;91(1):23–9.CrossRefPubMedCentralGoogle Scholar